Navigation Links
Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS)
Date:5/20/2013

Pocomoke, Maryland (PRWEB) May 20, 2013

In Early 2013, Dr. Ritchie Shoemaker, internationally recognized leader in the field of biotoxin related illnesses, announced his vision for creating a network of physicians across the country able to advance his protocol for treating Chronic Inflammatory Response Syndrome (CIRS). This week, Dr. Raj Patel became the third physician to achieve certification in the Shoemaker Protocol.

“Creating a network of Certified Physicians, able to practice the Shoemaker Protocol in other parts of the country, is enabling patients who need qualified medical help to find that help closer to home… Dr. Patel is a strong addition to the network, bringing the Protocol to the West Coast for the first time.” reported Dr. Shoemaker, who has been practicing in Maryland for decades. The Shoemaker Protocol is a step by step process of treating patients suffering from biotoxin related illnesses using differential diagnosis and proven scientific fundamentals. Dr. Shoemaker works one on one with candidates of the program to ensure a complete mastery of the practice.

Dr. Raj Patel, the third physician to become certified by Dr. Shoemaker, is a Rutgers University and Robert Wood Johnson Medical School graduate. He has specialized in treating patients with Autistic Spectrum Disorders (ASD), as well as Lyme disease, and more recently, biotoxin illness resulting from exposure to water damaged buildings. Since beginning his work with Autism in 1999, he has helped over 700 children, as well as working with other childhood developmental conditions including ADD/ADHD, OCD, and developmental delay. He is an active Member of Defeat Autism Now (DAN), and the International Lyme and Associated Diseases Society (ILADS).

According to Dr. Shoemaker, “The Shoemaker Protocol slowly brings back a life filled with meaning and fullness, vitality and insight, as the new therapies correct the immunologic disease often called mold illness.”

About Dr. Ritchie Shoemaker - Ritchie Shoemaker, MD, is an internationally recognized leader in education, patient care, and research in the field of biotoxin related illness, and has treated over 6,000 patients. Dr. Shoemaker has written numerous papers and eight books, including the widely read Surviving Mold, and Mold Warriors. After announcing his retirement from active patient care in January 2013, he has dedicated his time to developing a network of physicians certified in the Shoemaker Protocol, continuing his research in the biotoxin illness field, giving lectures and attending conferences on the subject.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10743966.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Dr. Ritchie Shoemaker Proudly Announces First Graduate of Shoemaker Protocol Certification Training
2. Dr. Ritchie Shoemaker Pleased to Announce Second Physician Achieves Shoemaker Protocol Certification for Treating Chronic Inflammatory Response Syndrome
3. Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
4. Fidelis Companies Certifies 14 Recruiters; Certified Personnel Consultant (CPC) and Certified Temporary-Staffing Specialist (CTS) Designation from NAPS Awarded
5. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
6. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Interleukin Genetics Reports Third Quarter 2011 Financial Results
9. Spherix Announces Third Quarter Financial Results
10. Nile Therapeutics Reports 2011 Third Quarter Financial Results
11. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from ... believe could be a new and helpful biomarker for malignant pleural mesothelioma. Surviving ... to read it now. , Biomarkers are components in the blood, tissue ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
Breaking Biology Technology:
(Date:6/22/2016)... 22, 2016 On Monday, the Department of ... to share solutions for the Biometric Exit Program. The ... Border Protection (CBP), explains that CBP intends to add ... the United States , in order to ... imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
Breaking Biology News(10 mins):